InterMune Jettisons Actimmune; Picks up $55M for Esbriet Work

InterMune Inc. agreed to sell its rights to Actimmune (interferon gamma-1b) to Vidara Therapeutics International Ltd. for $55 million in cash plus royalties for two years. InterMune's CEO Dan Welch said divesting Actimmune would free up capital for development and registration of Esbriet (perfenidone) in Europe and other territories, and support other research and development activities.